(Q34480200)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062928%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

title

Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062928%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062928%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Scott Kopetz

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062928%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Imad Shureiqi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062928%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

author name string

J Morris

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062928%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

N Parikh

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062928%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

W Qiao

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062928%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

M J Overman

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062928%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

D Fogelman

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062928%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

C Jacobs

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062928%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Z Malik

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062928%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

C A Jimenez

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062928%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

R A Wolff

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062928%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

J L Abbruzzese

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062928%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

G Gallick

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062928%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

C Eng

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062928%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

publication date

12 June 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062928%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

17 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062928%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062928%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062928%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

page(s)

977-984

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062928%20AND%20SRC:MED&resulttype=core&format=json

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

17 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

Transformation by v-Src: Ras-MAPK and PI3K-mTOR mediate parallel pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

Src-mediated aryl hydrocarbon and epidermal growth factor receptor cross talk stimulates colon cancer cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

The role of Src in colon cancer and its therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

Current status of SRC inhibitors in solid tumor malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0257-Z

A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer

21 January 2018

1 reference

12 December 2020

Colorectal cancer statistics, 2014.

1 reference

12 December 2020

Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

1 reference

12 December 2020

Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis

1 reference

12 December 2020

A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma

1 reference

12 December 2020